CA2283231A1 - Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation - Google Patents

Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Download PDF

Info

Publication number
CA2283231A1
CA2283231A1 CA002283231A CA2283231A CA2283231A1 CA 2283231 A1 CA2283231 A1 CA 2283231A1 CA 002283231 A CA002283231 A CA 002283231A CA 2283231 A CA2283231 A CA 2283231A CA 2283231 A1 CA2283231 A1 CA 2283231A1
Authority
CA
Canada
Prior art keywords
gene
adenoviral
adenovirus vectors
methods
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002283231A
Other languages
English (en)
Other versions
CA2283231C (fr
Inventor
Daniel R. Henderson
De-Chao Yu
Henry G. Lamparski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CG Oncology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/033,556 external-priority patent/US6432700B1/en
Application filed by Individual filed Critical Individual
Publication of CA2283231A1 publication Critical patent/CA2283231A1/fr
Application granted granted Critical
Publication of CA2283231C publication Critical patent/CA2283231C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002283231A 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Expired - Lifetime CA2283231C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3976397P 1997-03-03 1997-03-03
US3976297P 1997-03-03 1997-03-03
US60/039,762 1997-03-03
US60/039,763 1997-03-03
US5452397P 1997-08-04 1997-08-04
US09/033,556 US6432700B1 (en) 1997-03-03 1998-03-02 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US60/054,523 1998-03-02
US09/033,556 1998-03-02
PCT/US1998/004080 WO1998039464A2 (fr) 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Publications (2)

Publication Number Publication Date
CA2283231A1 true CA2283231A1 (fr) 1998-09-11
CA2283231C CA2283231C (fr) 2008-05-20

Family

ID=27488125

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283231A Expired - Lifetime CA2283231C (fr) 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Country Status (5)

Country Link
EP (1) EP1007715A2 (fr)
JP (1) JP2002514074A (fr)
AU (1) AU744725B2 (fr)
CA (1) CA2283231C (fr)
WO (1) WO1998039464A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0968298A2 (fr) * 1997-03-03 2000-01-05 Calydon, Inc. Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
DE69838584T2 (de) * 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
WO1999055365A1 (fr) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Vecteurs adenoviraux avec proteines a deux types de genes de fibre
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1112372A1 (fr) 1998-09-11 2001-07-04 Genvec, Inc. Adenovirus a ciblage altnernatif
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
AU6497799A (en) * 1998-10-15 2000-05-01 Canji, Inc. Methods and compositions to induce antitumor response
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
JP4404490B2 (ja) * 1998-10-15 2010-01-27 カンジ，インコーポレイテッド 選択的に複製するウイルスベクター
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
GB9906815D0 (en) 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
WO2001073093A2 (fr) * 2000-03-24 2001-10-04 Cell Genesys, Inc. Vecteurs adenoviraux a specificite cellulaire comprenant un site recepteur interne du ribosome
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
EP1318839A2 (fr) * 2000-03-24 2003-06-18 Cell Genesys, Inc. Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
US6673614B2 (en) 2000-06-27 2004-01-06 Cell Genesys, Inc. Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody
US20050124010A1 (en) * 2000-09-30 2005-06-09 Short Jay M. Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating
CA2439185A1 (fr) 2001-02-23 2002-09-06 Novartis Ag Nouvelles constructions de vecteurs
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
WO2004042025A2 (fr) 2002-11-01 2004-05-21 Cell Genesys, Inc. Vecteur d'adenovirus specifique des cellules comprenant un promoteur specifique de ebv
CA2516652A1 (fr) * 2003-02-24 2005-01-27 Cell Genesys, Inc. Systeme pour la commande externe de la reproduction d'un virus oncolytique
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
WO2011043719A1 (fr) * 2009-10-05 2011-04-14 Ya-Fang Mei Réplication de vecteurs viraux pour thérapie génique
EP3426271A4 (fr) 2016-03-10 2019-10-16 Cold Genesys, Inc. Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
KR20190134786A (ko) 2017-04-14 2019-12-04 콜드 제네시스, 인크. 방광암의 치료 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093699A (en) * 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9216851D0 (en) * 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
AU716045B2 (en) * 1994-11-28 2000-02-17 Genetic Therapy, Inc. Vectors for tissue-specific replication
WO1996021036A2 (fr) * 1994-12-30 1996-07-11 Chiron Viagene, Inc. Agents de concentration d'acide nucleique ayant une immunogenicite reduite
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors

Also Published As

Publication number Publication date
AU6345098A (en) 1998-09-22
CA2283231C (fr) 2008-05-20
AU744725B2 (en) 2002-02-28
WO1998039464A2 (fr) 1998-09-11
JP2002514074A (ja) 2002-05-14
WO1998039464A8 (fr) 1999-04-01
EP1007715A2 (fr) 2000-06-14
WO1998039464A3 (fr) 1999-01-07

Similar Documents

Publication Publication Date Title
CA2283231A1 (fr) Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
Sandig et al. Optimization of the helper-dependent adenovirus system for production and potency in vivo
ES2151310T3 (es) Nuevas lineas celulares de complementacion para vectores adenovirales defectivos.
ATE295739T1 (de) ADENOVIRALE VEKTOREN BEINHALTEND EIN PROSTATA SPEZIFISCHES ANTIGEN (PSA) ßRESPONSE ELEMENTß
ATE310829T1 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
CA2311643A1 (fr) Compositions et procedes induisant l'expression genique
ATE326540T1 (de) Trans-aktivierung und cis-aktivierung um die dauer der expression eines transgens zu modulieren
WO2000039319A3 (fr) Vecteurs adenoviraux specifiques de cellules cibles renfermant la sequence e3 et leurs methodes d'utilisation
EA199800566A1 (ru) Аденовирусный вектор (варианты), способ его получения, применение, репликационно-компетентное не содержащее аденовирус потомство, способ повышения размножения в комплементирующей клеточной линии аденовирусного вектора, способ генетической модификации клетки, композиция, клетка-хозяин, способ тестирования токсичности аденовирусного вектора, способ тестирования экспрессии чужеродного гена или гена-пассажира аденовирусного вектора
WO2005001103A3 (fr) Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
MX9709549A (es) Adenovirus recombinantes, su uso para preparar aav, linea celular complementaria y composiciones farmaceuticas que los contienen.
AU6572194A (en) Defective recombinant adenoviruses for gene therapy of tumours
AU543168B2 (en) Stabilizing and selecting recombinant dna host cells
WO1995027071A3 (fr) Systeme supervecteur adenoviral
FI951138A (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
AU5588298A (en) Adeno-associated viral vector-mediated delivery of dna to cells of the liver
AU3625997A (en) Chimeric gene containing several herbicide tolerance genes, plant cell and plant which are tolerant to several herbicides
DK136184D0 (da) Fremgangsmaade til udtrykkelse af et gen,der koder for prochymosin,i e.coli-vaertsceller og udtrykkelsesplasmid til brug ved fremgangsmaaden
WO2001036650A3 (fr) Adenovirus oncolytique
NZ508399A (en) Packaging cell lines for use in facilitating the development of high capacity adenoviral vectors
WO2001055362A3 (fr) Vecteur adeno-retroviral hybride pour la transfection de cellules
AU6139699A (en) Packaging cell lines for hiv-derived retroviral vector particles
TR199700535A3 (tr) Gemilerin havuza alinmasi için yüzer havuzlar.
WO1999053085A3 (fr) Regulation selective de la production d'adenovirus
WO2000049168A3 (fr) Vecteurs adenoviraux dependants d'assistants reposant sur des recombinases a regio-specificite

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180305